The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial:

Sara Bravaccini,Giuseppe Bronte,Emanuela Scarpi,Sara Ravaioli,Roberta Maltoni,Anita Mangia,Maria Maddalena Tumedei,Maurizio Puccetti,Patrizia Serra,Lorenzo Gianni,Laura Amaducci,Nicoletta Biglia,Valentina Elisabetta Bounous,Angelo Virgilio Paradiso,Rosella Silvestrini,Dino Amadori,Andrea Rocca

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial:

2020

Sara Bravaccini
Giuseppe Bronte
Emanuela Scarpi
Sara Ravaioli
Roberta Maltoni
Anita Mangia
Maria Maddalena Tumedei
Maurizio Puccetti
Patrizia Serra
Lorenzo Gianni
Laura Amaducci
Nicoletta Biglia
Valentina Elisabetta Bounous
Angelo Virgilio Paradiso
Rosella Silvestrini
Dino Amadori
Andrea Rocca

Background:In the Italian Breast Cancer Intergroup Studies (IBIS) 3 phase III trial, we compared cyclophosphamide, methotrexate, 5-fluorouracil (CMF) alone to sequential epirubicin/CMF regimens in ...

Keywords:

Epirubicin
Oncology
Progesterone receptor
Hormone receptor
Pharmacology
Methotrexate
Internal medicine
Post-hoc analysis
Immunohistochemistry
Breast cancer
Cyclophosphamide
Medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations